Zoetis (ZTS) : Thursdays money flow data in Zoetis (ZTS) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $4.23 million, whereas, $3.21 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.32, in favor of the bulls. The total money flow into the stock was $1.02 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $1.22 million. The total value of block trades done on upticks was $1.22 million. Zoetis (ZTS) fell $0.17 and traded at $47.92, down -0.35% for the day, over previous days close. On a weekly basis, the shares are 0.99% over the previous weeks close.
Zoetis (ZTS) : 8 investment research analysts covering Zoetis (ZTS) have an average price target of $53.13 for the near short term. The highest target price given by the Brokerage Firm to the stock is $62 and the lowest target is $45 for the short term. Analysts expect the variance to be within $5.72 of the average price. The stock has recorded a 20-day Moving Average of 1.21% and the 50-Day Moving Average is 1.16%.
Zoetis (NYSE:ZTS): The stock opened at $48.10 on Thursday but the bulls could not build on the opening and the stock topped out at $48.17 for the day. The stock traded down to $47.46 during the day, due to lack of any buying support eventually closed down at $47.69 with a loss of -0.83% for the day. The stock had closed at $48.09 on the previous day. The total traded volume was 2,338,037 shares.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.